Literature DB >> 9752269

[Targeting the gene of glucose metabolism for the treatment of advanced gliomas].

S Oudard1, L Miccoli, B Dutrillaux, M F Poupon.   

Abstract

Loss of chromosomes is a recurrent event in cancer. Chromosome-10 losses occur with tumor progression and characterize advanced gliomas. This chromosome carries many genes involved in glucose metabolism. Hexokinase (HK) gene is located on chromosome-10. Hexokinase enzymatic activity is decreased in glioblastomas. Hexokinase enables glucose entry into glycolysis and is critical for these highly glycolytic tumors. These enzyme is either free in the cytosol or bound to the mitochondrial outer membrane. Disturbance of HK binding to mitochondria by lonidamine led to inhibition of cells and xenografted-glioma growth. Hexokinase bind to a mitochondrial porin which involved peripheral benzodiazepine receptors. Inhibition of HK and peripheral benzodiazepine receptors by lonidamine and diazepam led to synergistic antitumoral activity in xenografted gliomas. Co-inhibition of these two receptors will lead to a decrease in glycolysis, often elevated in these tumors, without modifying energetic metabolism of normal cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9752269

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

1.  Effect of diazepam on the efficacy of dual-phase FDG PET imaging.

Authors:  Hongming Zhuang; R Hustinx; A Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02       Impact factor: 9.236

2.  Gold(I) Complexes with a Quinazoline Carboxamide Alkynyl Ligand: Synthesis, Cytotoxicity, and Mechanistic Studies.

Authors:  Leila Tabrizi; Won Seok Yang; Chetan Chintha; Liam Morrison; Afshin Samali; Joe W Ramos; Andrea Erxleben
Journal:  Eur J Inorg Chem       Date:  2021-05-11       Impact factor: 2.524

3.  Use of benzodiazepines before (18)F-FDG-PET/CT dual-phase imaging does not decrease the efficacy of the study.

Authors:  Filiz Ozülker; Tamer Ozülker; Tevfik Ozpaçacı
Journal:  Indian J Nucl Med       Date:  2012-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.